https://doi.org/10.55788/ac2605e6
Neoadjuvant degarelix plus apalutamide outperformed degarelix alone in patients with high-risk prostate cancer who were planned to receive a radical prostatectomy. The results of the phase 2 ARNEO trial encourage the development of phase 3 trials to further explore degarelix plus apalutamide in this population [1].
“Even with the current therapies, there is a huge unmet need for patients with high-risk prostate cancer,” said Prof. Steven Joniau (UZ Leuven, Belgium). A retrospective analysis suggested a survival benefit of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with high-risk disease [2]. To confirm the results of this study prospectively, the phase 2 ARNEO trial (NCT03080116) was designed, which randomised 89 patients with high-risk prostate cancer to 3 months of neoadjuvant degarelix plus apalutamide therapy or to degarelix alone, prior to their radical prostatectomy.
The primary endpoint, the proportion of patients with minimal residual disease (<0.25 mL) after neoadjuvant treatment, was met. In the experimental arm, 38% of the patients displayed minimal residual disease after treatment compared with 9% in the placebo arm (RR 4.2; P=0.002). Correspondingly, the median residual cancer burden was 1.7 mL in the placebo arm and 0.48 mL in the experimental arm. Furthermore, downstaging to pT2-disease occurred more often in the apalutamide arm than in the placebo arm (51% vs 27%; P=0.03). The authors found that PSMA levels and residual cancer volume were correlated, suggesting that PSMA has a monitoring role in future neoadjuvant trials. Finally, PTEN gene loss was associated with poor response to therapy (11% vs 43%; P=0.002).
Prof. Joniau concluded that the results of this phase 2 trial justify the development of phase 3 trials assessing neoadjuvant hormonal therapy in patients with high-risk prostate cancer.
- Devos G, et al. Randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for unfavorable intermediate- and high-risk prostate cancer. Game-changing session 3, EAU 2022, 01–04 July.
- Tosco L, et al. Prostate Cancer Prostatic Dis. 2017;20:407-412
Copyright ©2022 Medicom Medical Publishers
Posted on
« Darolutamide performs well across subgroups in mHSPC Next Article
PROpel: Good results for abiraterone plus olaparib in mCRPC »
Table of Contents: EAU 2022
Featured articles
Darolutamide performs well across subgroups in mHSPC
Genitourinary Cancer
Does systematic biopsy add value to the detection rate of prostate cancer?
PSMA PET/CT cannot replace mpMRI for diagnosis of prostate cancer
Prostate cancer treatments reduce quality of life
PROpel: Good results for abiraterone plus olaparib in mCRPC
Neoadjuvant hormonal therapy promising in high-risk prostate cancer
Darolutamide performs well across subgroups in mHSPC
Shorter hospital stay with robotic surgery versus open surgery in bladder cancer
Improved risk stratification for high-risk NMIBC
Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma
New prognostication in N3 penile cancer
KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC
Fewer complications with robotic surgery in renal cancer
Functional Urology
Novel therapeutic targets for benign prostatic hyperplasia
Mini-slings non-inferior to standard mid-urethral slings in SUI
Non-inferiority of methenamine hippurate to antibiotics in recurrent UTIs
Related Articles
Allopurinol treatment for gout appears safe in kidney patients

© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy